Calculus Capital’s investment in Synpromics was featured in national Scottish newspapers The Scotsman and The Herald.

Synpromics is a Edinburgh-based synthetic biology company which Calculus Capital has backed for a second time, leading the new round with a £3.5m investment alongside backing from Scottish Enterprise and a group of private investors.

The Scotsman spoke of the research collaboration with industry giant GE Healthcare: The tie-up will see the firm create a “toolbox”, using GE Healthcare’s Chinese hamster ovary cell platform, aimed at helping to develop a range of biopharmaceuticals, including difficult-to-manufacture proteins. It said the bulk of its fresh funding will be used to develop its PromPT platform, which enables the design of “synthetic promoters” that give precise control of gene functions in areas such as gene therapy, cell therapy and gene editing.

The Herald quoted Chief Executive of Calculus Capital, John Glencross: “Since our initial investment in 2015, its performance as a business has been outstanding, with many positive developments, both commercially and in its research, which are putting it on the radar of the major players in life sciences both in Europe and the US.”

Read the full articles here –